Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have no idea what he has done so far.
He has contacts around the world that may very well open doors for Precipio. I am a patient long term investor, not a trader.
I would think he is not just collecting a paycheck. That's the problem with the world we live in. Everyone has to have it RIGHT NOW!
JDHeart…
Make a choice...
these guys really pounding i am a buyer
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149747194
.17 coming soon , then its a spec buy
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149764470
Really Dennis.
Who makes this stuff up?
Ori Karev, who was CEO of United Healthcare Global, would risk his reputation and come to a worthless company that is facing Nasdaq delisting because they offered him a job? Really?
Maybe, he sees a lot of potential with PRPO, and sees a chance to grow this company into a multi-million dollar company. This makes A LOT MORE SENSE than what you have flippantly offered. I believe this company is on the rader of a lot of people, waiting for the right moment.
Shorty, beware!
Allright Dennis, if this company is so bad, and the CEO is so stupid as you say, why did this happen?
https://finance.yahoo.com/news/mr-ori-karev-joins-precipio-124500055.html
No, it is your friends at LPC, shorting this down, making money all the way, and then hoping to cover when PRPO accesses the line of credit.
This, in case you don't know, is the way America works, with Hedge funds trying to bankrupt small innovative companies for their profit, and then buying them for pennies on the dollar. When an agreement is signed, their will be a huge short squeeze.
Did you know, or just conveniently forget, that Precipio was saddled with over 20 million dollars of debt from Craig Tuttle and Transgenomic, and no cash Btw, which the current CEO, Ilan Danelli masterfully whittled down under I believe 5 million? This company is turning around wether you like it or not.
They will not be kicked off the Nasdaq as you are hoping for, they will have at least 6 more months and probably a year to regain compliance. It ain't going under a dollar anyway!
Those items prove the company is turning around, and you just do not want to see it. What do you suppose would happen if PRPO announced a licensing agreement with, say Quest or someone of their stature. The price would skyrocket. This is the reason why LPC will never short this under a dollar, no matter how hard they try. So your incessant callings for a RS are not gonna happen.
Show me a link where it is too soon and they will be kicked off the Nasdaq.
Even your friends at LPC will not be able to short this down to under a dollar again. Not gonna happen!
Have you ever heard of Transgenomic?
Its funny because its not going to 20 cents.
But you know this.
As usual, you ignore everything I say and go back to your reverse split agenda.
I said that if it ever did get back under a dollar, it would take another year before they would have to do another reverse split, and you insinuate that a reverse split is coming in weeks.
If it ever dropped below a dollar again, which is never going to happen, it would be another year before they would have to do a reverse split again to remain on the Nasdaq. But you know this.
20 cents.
Now that's funny.
When the dead money has it's resurrection, it will put your bull market out to pasture.
I guess Bloomberg thinks Falcon Capital is a scam too....
https://www.bloomberg.com/profile/person/16999170
https://www.bloomberg.com/profile/person/20738359
https://www.bloomberg.com/research/stocks/private/person.asp?personId=42185708&privcapId=34251667
On to the finish line. Peace to all Reg 2015 Have a great 4th and remember our protectors. May God watch over them all.
Amen to that!
A couple of people shorting Precipio
You've got to be kidding me. Do you have any idea how hedge funds work? They give a line of credit to a stock, short it down as low as possible, and then cover with the line of credit.
Its even better if they can bankrupt the company, and never have to cover.
If you really think this is a couple of people shorting Precipio, you are mistaken. But then again, I believe you know this.
/
I guess it's you then.
LPC must be proud of your work.
Btw, this is not Transgenomic anymore, if you even know who they were. And, no there will not be another reverse split, so you can quit saying there will be.
I think you are way ahead of yourself talking about another reverse split.
I don't know which of you 2 works for LPC, but I am positive it is one of you, or maybe both. This company has a lot going for it, and is being shorted by LPC, because of the line of credit. There is no way a company like this should have a market cap of 25 million dollars.
This is childish....
It's not Jefferies, but I'll take it.
Ben Haynor is a top notch analyst.
https://www.biotuesdays.com/briefs/2019/6/20/alliance-global-starts-precipio-at-buy-pt-630
Alliance Global starts Precipio at buy; PT $6.30
Alliance Global Partners launched coverage of Precipio (NASDAQ:PRPO) with a “buy” rating and price target of $6.30. The stock closed at $3.12 on June 19.
Precipio has staked out a unique position within blood-related cancer diagnostics and is heavily focused on preventing misdiagnosis.
Analyst Ben Haynor writes that the company has developed a pathology services business where its laboratory performs the technical component, representing about 80% of reimbursement, while expert academic pathologists perform the professional component, representing about 20% of reimbursement.
“To this end, the company has developed relationships with thought-leading institutions, including an exclusive agreement with the Department of Pathology at Yale University, which was recently renewed for five additional years,” he added.
Mr. Haynor said genomic characterization and improved diagnostic imaging have benefited solid-tumor cancer misdiagnosis rates over the past several decades, with some improvements in blood cancer diagnostics.
However, older studies in blood cancers have found discordance rates north of 40% in autopsy studies and over 50% in comparing primary pathologist diagnosis with centralized pathology review.
Studies from the UK, MD Anderson Cancer Center, and Precipio have shown discordance rates ranging from 17% to 27.3% comparing primary pathology to centralized review.
“We believe the true discordance rate in blood cancer falls in the low-20% range based on multiple studies,” Mr. Haynor said. “Further, we estimate a proper initial diagnosis would change treatment decisions in about 45% to 75% of discordant cases.”
“These data support centralized pathology review in clinical practice, which is “effectively Precipio's model in their pathology services business,” he added.
In addition, he said Precipio is conducting a 1,000-plus patient trial, which should complete enrollment later this year. Initial data should be available shortly afterwards and publication in a peer-reviewed journal to follow several months later. “We would view positive results as a significant catalyst for the company and further validate their model,” he added.
In addition to its pathology services business, Mr. Haynor said Precipio has developed two proprietary products addressing their own pain points, each of which represents annual markets in the $50-million to $100-million range.
HemeScreen allows for cost-effective and rapid screening of the four genes recommended in the guidelines by the National Comprehensive Cancer Network for patients with myeloproliferative neoplasms and myelodysplastic syndromes.
Most labs batch these tests for cost reasons, leading to two-to-four week turnaround times, while HemeScreen can provide the same information in two-to-four days or less and is profitable at Medicare reimbursement rates of about $600 per panel.
The company has also developed IV-Cell, a culturing media for all four hematopoietic cell lineages at once, compared with the existing dominant culture media, MarrowMAX from Thermo Fisher, which allows for culturing of only one cell lineage at a time.
According to Precipio, a large laboratory is evaluating IV-Cell and it expects to have multiple clients by the end of the year following a third quarter launch, which “we believe could offer upside to our estimates,” Mr. Haynor added.
Sure doesn't take long for them to dump this stock into the market.
I guess we should be happy the market is absorbing it pretty well....So far!
They finally let the price out for the Cryogene acquisition, 20.5 million.
So basically they needed money. No surprise there. Seems Jefferies isn't giving you a recommendation w/o expecting something in return. Now, they got it. Just depends what they do with the money.
Cryogene seems to be putting a foot in the door of the BLFS space. They seem to be expanding from the cryogenically frozen area.
Lets see what they make of this.
This is spot-on!
Not a one trick pony, it is a new immunotherapy platform.
Have you looked at the data from the 2018 SNO conference?
Compare that to Novocure data, which is the only thing approved in years.
I agree with you on NWBO management. That is the knock of the naysayers, pick on management, because you have a rough time picking on the science.
GBM has nothing, and a 3 month improvement is monumental. NVCR and their helmut got approved, and it seems everyone else is failing. Data looks great!
Like that it is up 45%, and closed near the high of the day.
Need Sojourner 55 to do a chart....
That does seem like a good supposition....
I sold all I had on the runup. Was out at 16.
I still have some non tradeable warrants I exercised from an offering I got in, that were set to expire in July 2020. Cant sell those for 5 more months, so I guess I am still in, but not by choice, but by SEC rule. May work out for the best, who knows.
Still waiting for NWBO. You still in that one?
Atta boy, Bio...LOL
I had a bid for 50,000 at $.242.
The low of the day was $.2421.
I bought 20,000 at $.27 yesterday.
Spot on!
Why some praise him and give him credibility, especially to newbies trying to get information on NWBO, I will never understand.
Yes, Senti, it ain't.
Let's give back 40 million shares and all the warrants, and sell the 12 million for 32 cents. Brilliant, what an outstanding way to run your business.
OMG.... I said contract. I made an error.
I'll alert the media.
While you are talking about misrepresentation, you also need to go to the penalty box for calling this a zero.it is far from a zero. Also didnt mention PRPO beat out ddPcr to be DOD VENDOR
I also noticed that you didnt try to bash the other links. LPC expects more out of its employees.
Maybe you can enlighten us as to what it means.
NEW HAVEN, Conn., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has been approved by the United States Department of Defense (DoD) as a domestic vendor within the Foundation for the Advancement of military medicine. Approval as a vendor will enable DoD funded medical centers to utilize Precipio ICE COLD-PCR (ICP) technology in mutation testing for both active duty as well as military veterans.
A hospital within the DoD evaluated several technologies including the competing Droplet Digital PCR (ddPCR), and ultimately decided that Precipio’s ICE-COLD PCR (ICP) enrichment technology for liquid biopsies was to be used at its facility. Precipio has received its first order, and anticipates delivery in January.
This doesn't look like zero to me. Everyone has to start somewhere, and they beat out ddPCR, which is a good competing technology.
Lot you know, Denunzio.
They have let out a lot of info, and it looks really promising.
Kinds have to read between the lines, but the info is there.
This weekend is ASCO, so I am looking on at least an update on the trial.